Effect of tobacco on INR [2]

American Journal of Health-System Pharmacy

Volumn 64, Issue 8, 2007, Pages 805-

  Stading, Julie A ^a   Faulkner, Michele A ^a   Skrabal, Maryann Z ^a   Chock, Alan ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISONE; TOBACCO SMOKE; WARFARIN;

ANTICOAGULATION; DRUG CLEARANCE; DRUG METABOLISM; EVIDENCE BASED MEDICINE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; PRIORITY JOURNAL; SMOKING CESSATION; TOBACCO;

EID: 34247279165     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070051     Document Type: Letter

References (8)

1. Mungall DR, Ludden TM, Marshall J et al. Population pharmacokinetics of racemic warfarin in adult patients. J Pharmacokinet Biopharm. 1985; 13:213-27.
2. Miller LG. Recent developments in the study of the effect of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics. Clin Pharmaco kinet. 1989; 17:90-108.
3. Kuykendall JR, Houle MD, Rhode RS. Possible warfarin failure due to interaction with smokeless tobacco. Ann Pharmacother. 2004; 38:595-7.
4. Evans M, Lews GM. Increase in international normalized ratio after smoking cessation in a patient receiving warfarin. Pharmacother. 2005; 25:1656-9.
5. Colucci VJ, Knapp JF. Increase in international normalized ratio associated with smoking cessation. Ann Pharmacother. 2001; 35:385-6.
6. Warfarin: INR elevation associated with smoking cessation: case report. Reactions. 2006; 1:25.
7. Lee V, You J, Lee K et al. Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients. J Thromb Thrombolysis. 2005; 20:33-8.
8. FAQs about warfarin. www.clotcare.com/ clotcare/aboutwarfarin.aspx (accessed 2007 Feb 19).